Immupharma PLC - Corporate Update - Replacement
("ImmuPharma" or the "Company")
CORPORATE UPDATE - replacement
The 'Corporate Update' announcement released on
Lupuzor™ is the Company's late stage asset for Lupus, a potential life threatening auto-immune disease. Following the conclusion of the pivotal Phase III trial in 2018, ImmuPharma continues to look at opportunities which the Board believes over the longer term have the potential of bringing Lupuzor™ to market. As part of this strategy, the Company confirms that it continues to engage with potential corporate partners as well as consulting with regulatory advisors on potential pathways to market. Whilst these activities continue the commencement of the Managed Access Program for Lupuzor™ will be postponed until the Company has further clarification on these activities.
Lupuzor™ Extension Study
The Lupuzor™ open label extension study, from the original Phase III trial, with a total of 62 eligible patients recruited throughout the US and Europe, remains on track to report results in Q2 2019.
Merger of Elro Pharma and Ureka
ImmuPharma's subsidiaries Elro Pharma Sarl and Ureka Sarl, both based in France, are focussing on unique technologies: the Nucant cancer programme (Elro) and the peptide platform (Ureka).
As previously announced, the Company has been exploring its options to licence, divest or 'spin-off' the technologies of both of these subsidiaries to unlock their future potential and enhance value to shareholders.
Following an internal review, the Company's intention is to merge these two subsidiaries, in order to create a stronger combined company with a platform technology together with a drug candidate in clinical development, with a view to securing external investment either from private equity or through a public listing on a
Further to the announcement of
ImmuPharma will provide a further update on its operations and strategy in its Final results for the year ended
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact:
Notes to Editors
ImmuPharma (AIM: IMM) is a pharmaceutical development company listed since 2006 on AIM of the
Lupuzor™ (also referred to as Forigerimod, or P140) is ImmuPharma's lead compound and a potential treatment for lupus (or Systemic Lupus Erythematosus), a chronic, potentially life-threatening auto-immune disease. Lupuzor™ has a novel mechanism of action aimed at modulating the body's immune system so that it does not attack healthy cells, and avoids causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients.
The completed pivotal Phase III clinical trial was entitled "A 52-Week, Randomized, Double-Blind,
ImmuPharma together with Professor Sylviane Muller, Lupuzor's inventor, have presented evidence supporting Lupuzor's™ Forigerimod / P140 peptide activity in several other major auto-immune disease indications outside of Lupus including Rheumatoid Arthritis, Crohn's Disease, and Asthma. In particular, the peptide appears to have general effects against chronic inflammatory indications. Other pre-clinical evidence supports the molecule's use in: Neuropsychiatric lupus (NPSLE); Gougerot-Sjögren syndrome (GSS); and Guillain-Barre disease (chronic/CIDP).
For more information, please visit www.immupharma.co.uk
This information is provided by RNS, the news service of the
Quick facts: ImmuPharma PLC
Market Cap: £24.33 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE